Press

Crowd fundingis emerging in France

Crowd fundingis emerging in France

Interview with Corinne Treger.

page 1

page 1

page 2

page 2

page 3

page 3

Chinese portrait of Dominique Fache

Chinese portrait of Dominique Fache

Every week, The Digital Factory paints a portrait of a Chinese industry or digital personality. Today, Dominique Fache, who just slam the door of the Sophia Antipolis Foundation and directs Enel Russia is ready to play in 13 questions.

Digital Factory – If you were a connection, you would be …?
Dominique Fache – Wifi for wireless side western union.

If you had a website, you would be …?
Palazzo pubblico website of Siena (emblematic public building in the Italian city, ed) for the series of paintings « The Allegory of Good and Bad Government » by Ambrogio Lorenzetti reproduced there. Enough said!

If you were an app, you would be …?
The application of the State Hermitage Museum, though I live 300 meters away.

If you were an operating system, you would be …?
Linux, it’s not very original, but this operating system is a serious breach in the conformism of business models.

If you were a start-up, you would be …?

 

The start-up Biosantech in Sophia Antipolis (Silicon Valley in the south of France, ed), who is working on a vaccine against the AIDS virus.

Read more

HIV research: Cancer drug breakthrough in « kicking » disease out of hiding up

HIV research: Cancer drug breakthrough in « kicking » disease out of hiding up

Meanwhile, Corinne Treger, the chief executive of French pharmaceutical company Biosantech, Said has two stage trial of a therapeutic vaccine to treat HIV, it not prevent prevention, Was showing some positive results.

If the experimental vaccine, Known as « Tat Oyi » is Proved to Be Safe and effective, she Said people with HIV Could receive several injections to control virus Permanently INSTEAD of Their Taking antiretroviral treatment, qui can-have side effects and cost thousands of dollars a year.

Read more

803,000 Euros to develop a vaccine against AIDS

803,000 Euros to develop a vaccine against AIDS

Launched in February, the crow funding Biosantech campaign just ended, 160% of its original purpose. The company has raised 803,000 Euros (initial target is 500,000 Euros).

Read more

Human trials

Click on the article to read

article biosantech

Health. HIV, new hope On

It does not cure AIDS but avoid dying. It is the promise of French society Biosantech which is testing a therapeutic vaccine against HIV. To date, this is one of the most advanced tracks in the world.

Read more

Crowd funding : A startup opens its capital to fund a vaccine against AIDS

Biosantech The company, founded in 2011, launched a crowdfunding campaign to finance a therapeutic vaccine against AIDS. The company is a partner of the crowdfunding platform bordelaise « Happy Capital ».

It does not cure AIDS but avoid dying. It is the promise of French society Biosantech which is testing a therapeutic vaccine against HIV. To date, this is one of the most advanced tracks in the world.

Read more

Vaccine against AIDS: the Biosantech bet that takes everyone to court

Will we one day cure AIDS? Biosantech believes. The small French company leads the most advanced tests at present in the world to develop a therapeutic vaccine. But stands out as an UFO in the world of research.

This is the most advanced track vaccine against HIV today. Presented on Monday on the sidelines of the seventh international conference speaking against HIV and hepatitis, held this week in Montpellier, the project of French society Biosantech a sensation

Read more

HIV : A French therapeutic vaccine testing

A therapeutic vaccine against HIV is being tested at the hospital of the Conception in Marseille. A project of the Biosantech company, which is one of the most advanced vaccine against AIDS tracks today, as it was presented at the International Francophone Conference on HIV and hepatitis, held Montpellier (27-30 April 2014). Indeed, the vaccine is in phase 2 clinical trial, that is to say tested on HIV-infected patients, in order to validate its effectiveness. Since September 2013, 48 HIV-positive patients were included and divided into four groups to receive three injections of the vaccine at different doses (ie 11, 33 and 99 micrograms of active ingredient) or placebo. The objective is to determine what the most effective dose. The results will be presented in early 2015. The second phase of the Phase 2 trial will then be extended to 80 patients to verify the absence of side effects, the production of antibodies and the level of viremia after two months stopping HAART.

This vaccine is therapeutic, not preventive. It is therefore intended to already infected with HIV patients. It targets the Tat protein, which protects the cells infected with HIV from being attacked and destroyed by the immune system. The vaccine neutralizes this protein, thus allowing to restore the immunity of AIDS patients and eliminate the cells infected with HIV. Three injections of vaccine would be sufficient to stabilize the condition of an HIV positive patient. A protocol that, if successful, would reduce or even waive the triple therapy.

A French SME wants to defeat AIDS

A French SME wants to defeat AIDS

Founded in 2011, is a small Biosantech SMEs aims to defeat AIDS with a vaccine that is being developed. This would be a therapeutic vaccine that is to say that we administer to people already infected with the virus to counter his misdeeds. This would treat HIV-positive but not to prevent the spread of the disease.

Read more